H g K g E cha ge a d C ea g L ed a d The S c E cha ge f H g K g L ed a e e , b f he c e , f h a ce e , a e e e e a a , acc ac c e e e , a d e e , d ca a ab ha e f a , h e a g f e a ce he h e a a f he c e , f h a ce e .

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a c ed c a c a ed he Pe e' Re b c f Ch a h ed ab)

(Stock Code: 02196)

2019 THIRD QUARTERLY REPORT

T R 13.09(2) R 13.10B R G L S T S E H K L I I P P I A S F O (C . 571 L H K).

T 2019 S F P (G) C ., L * ("Company", "Group") ("2019 Third Quarterly Report"). T PRC A S B E

B B

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Cha a

S , P ' R C

29 O 2019

A a he da e f h a ce e , he e ec e d ec f he C a a e M . Che Q , M . Ya Fa g a d M . W Y fa g; he -e ec e d ec f he C a a e M . X X a a g, M . Wa g Ca , M . M Ha g a d M . La g J a fe g; a d he de e de -e ec e d ec f he C a a e M . J a g X a , D . W g T Ya Ke , M . L L g a d M . Ta g G a g.

* *f de f ca e*

1. IMPORTANT NOTICE

1.1 T [illegible] (**"Board"**) [illegible] (**"Supervisory Committee"**) [illegible] C [illegible] 2019 T [illegible] Q [illegible] R [illegible] G [illegible]

1.2 A [illegible] C [illegible] B [illegible] 2019 T [illegible] Q [illegible] R [illegible] G [illegible].

1.3 C [illegible] Q [illegible] C [illegible], G [illegible] C [illegible] F [illegible] O [illegible] C [illegible] D [illegible] A [illegible] D [illegible] (A [illegible] O [illegible]) [illegible] 2019 T [illegible] Q [illegible] R [illegible] G [illegible].

1.4 T 2019 T [illegible] Q [illegible] R [illegible] G [illegible]

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

2.1 M [illegible]

[illegible] G [illegible]: RMB

	30 September 2019	31 December 2018	Ratio of change (%)
T [illegible]	78,569,297,725.65	70,551,361,387.48	11.36
N [illegible]	30,633,746,877.27	27,977,736,427.49	9.49
	Jan – Sept 2019	**Jan – Sept 2018**	**Period-on-period change (%)**
N [illegible]	2,328,355,784.17	2,087,826,458.74	11.52
	Jan – Sept 2019	**Jan – Sept 2018**	**Period-on-period change (%)**
O [illegible] R [illegible]	21,227,618,679.11	18,142,384,871.95	17.01
N [illegible]	2,063,704,147.99	2,094,152,353.81	–1.45
N [illegible]	1,722,388,028.34	1,591,668,096.39	8.21
[illegible] (%)	7.21	8.00	D [illegible] 0.79 [illegible]
B [illegible] (RMB/ [illegible])	0.81	0.83	–2.41
D [illegible] (RMB/ [illegible])	0.81	0.83	–2.41

N[illegible]e: I [illegible] 2019, [illegible] ([illegible] L T [illegible]), [illegible] (B [illegible]), [illegible] I [illegible] F [illegible] ' D [illegible] . T [illegible] G [illegible] RMB554.7841 [illegible], [illegible] RMB163.7726 [illegible] 41.88%. T [illegible] R [illegible] P [illegible] RMB1,722.388 [illegible], [illegible] RMB130.7199 [illegible] 8.21%.

D [illegible] RMB–7.1998 [illegible], [illegible] RMB149.8699 [illegible]; [illegible] R [illegible] P [illegible] RMB341.3161 [illegible], [illegible] RMB161.1681 [illegible] 32.07%.

B [illegible] , [illegible] R [illegible] P [illegible] RMB30.4482 [illegible], [illegible] 1.45%.

D [illegible] R [illegible] P [illegible] G [illegible] RMB2,253.454 [illegible], [illegible] RMB386.4802 [illegible] 20.70%; [illegible] RMB2,328.3558 [illegible], [illegible] 11.52% [illegible] 2018.

E [illegible]

[illegible] G [illegible]: RMB

Items	Jul – Sept 2019	Jan – Sept 2019
G [illegible]	6,698,974.15	54,877,229.54
G [illegible] C [illegible]	64,610,828.53	123,804,343.06
P [illegible] C [illegible]	–95,402,673.43	231,996,093.58
N [illegible]	48,756,541.22	27,391,712.25
I [illegible]	–15,445,568.08	–33,058,160.48
E [illegible]	–16,417,943.49	–63,695,098.30
T [illegible]	–7,199,841.10	341,316,119.65

The shareholding status of the Top 10 unrestricted shareholders			
Name of the shareholders	**Number of unrestricted tradable shares held**	**Type and number of shares**	
		Type	**Number**
SHANGHAI FOS N HIGH TECHNOLOG (GRO P) COMPAN LIMITED*	938,095,290	RMB [illegible]	938,095,290
HKSCC NOMINEES LIMITED *(N e 1)*	551,255,448	O [illegible]	551,255,448
CHINA SEC RITIES FINANCE CORPORATION LIMITED*	38,736,157	RMB [illegible]	38,736,157
HONG KONG SEC RITIES CLEARING COMPAN LIMITED *(N e 2)*	36,199,707	RMB [illegible]	36,199,707
NATIONAL SOCIAL SEC RIT F ND 113 PORTFOLIO*	28,066,210	RMB [illegible]	28,066,210
BASIC PENSION INS RANCE F ND 802 PORTFOLIO*	25,824,892	RMB [illegible]	25,824,892
CENTRAL H IJIN ASSET MANAGEMENT LTD.*	24,067,700	RMB [illegible]	24,067,700
NATIONAL SOCIAL SEC RIT F ND 110 PORTFOLIO*	15,358,518	RMB [illegible]	15,358,518
AB DHABI IN ESTMENT A THORIT	13,790,532	RMB [illegible]	13,790,532
CHINA CONSTR CTION BANK CORPORATION－CHINA-E ROPE AL E DISCO ER EQ IT SEC RITIES IN ESTMENT F ND*	10,198,273	RMB [illegible]	10,198,273
D [illegible]	T C [illegible]		
D [illegible]	N [illegible]		

N e 1: HKSCC NOMINEES LIMITED, [illegible] H [illegible] K [illegible] S [illegible] C [illegible] C [illegible] N [illegible] L [illegible] R [illegible] P [illegible] 34,993,500 H [illegible] C [illegible] S [illegible] F [illegible] H [illegible] T [illegible] (G [illegible]) C., L [illegible]* (“**Fosun High Tech**”) [illegible] 1.37% [illegible] C [illegible] R [illegible] P [illegible]

N e 2: HONG KONG SEC RITIES CLEARING COMPAN LIMITED [illegible] RMB [illegible] S [illegible] -H [illegible] K [illegible] S [illegible] C [illegible].

2.3 T [illegible] T [illegible] 10 [illegible] T [illegible] 10 [illegible] C [illegible] R [illegible] P [illegible]

N [illegible]

3. SIGNIFICANT EVENTS

3.1 S[illegible] G[illegible]

(1) B[illegible] S[illegible]

[illegible]: [illegible] G[illegible]: RMB

Balance Sheet				
Items	**30 September 2019**	**31 December 2018**	**Ratio of change**	**Reasons of changes**
F[illegible]	1,344,673,568.10	616,123,764.39	118.25%	M[illegible] R[illegible] P[illegible]
B[illegible]	258,620,513.78	712,510,581.95	–63.70%	M[illegible] "[illegible]" [illegible] R[illegible] P[illegible]
R[illegible]	471,597,865.70	—	N/A	M[illegible] "[illegible]" [illegible] M[illegible] F[illegible] P[illegible]' R[illegible] C[illegible] "**MOF**

(3) [illegible] C[illegible] F[illegible]

[illegible]: RMB

Statement of Cash Flow				
Items	**Jan – Sept 2019**	**Jan – Sept 2018**	**Ratio of change**	**Reasons of changes**
N[illegible]	–2,560,243,375.55	–4,338,289,449.60	40.98%	M[illegible] SHL [illegible] CMF [illegible] R[illegible] P[illegible]
E[illegible]	47,762,255.60	–31,014,791.25	254.00%	M[illegible] R[illegible] P[illegible]

3.2 A[illegible]

1. T[illegible] 2016 [illegible] C[illegible] RMB10 [illegible] T[illegible] N[illegible] A[illegible] R[illegible] (Z[illegible] S[illegible] Z[illegible] 2018 MTN N[illegible] 208 [illegible] S[illegible] 2018 SCP N[illegible] 90) [illegible] N[illegible] A[illegible] F[illegible] M[illegible] I[illegible] I[illegible] 17 A[illegible] 2018, [illegible] C[illegible] RMB5 [illegible] T[illegible] 2 [illegible] M[illegible]

   T[illegible] S[illegible] F[illegible] P[illegible] (G[illegible]) C[illegible], L[illegible]* 2019 [illegible] C[illegible] 29 J[illegible] 2019 [illegible] RMB300 [illegible] 3.00%.

2. O[illegible] 19 S[illegible] 2019, [illegible] C[illegible] F[illegible] H[illegible] T[illegible], F[illegible] H[illegible] T[illegible] ([illegible]) [illegible] C[illegible] ([illegible] A [illegible] H[illegible]) [illegible] S[illegible] S[illegible] E[illegible] ([illegible] S[illegible]-H[illegible] K[illegible] S[illegible] C[illegible]) [illegible] 19 S[illegible] 2019 [illegible] 18 S[illegible] 2020, [illegible] RMB100 [illegible] T[illegible] 2% [illegible] C[illegible] 19 S[illegible] 2019 ([illegible] 2,562,898,545 [illegible]) ([illegible] C[illegible] 12-[illegible] 2% [illegible] C[illegible]).

A R P F H T 2,560,000 H C RMB53.54 0.10% C 19 S 2019.

3. O 27 N 2018, 2018 C S H B I (“**Shanghai Henlius**”), (H) M B T S E H K L (“**Hong Kong Stock Exchange**”).

O 25 S 2019, H K S E H S H M B H K S E S H 64,695,400 H HK$49.60 G O ( ) HK$3,208.89 A 30 S 2019, S H C ( ) 53.76%.

O 17 O 2019, S H 4,366,400 H HK$49.60 HK$210.49 S H C ( ) 53.33%.

3.3 F R P

N

3.4

N

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
L R : **Chen Qiyu**
29 O 2019

4. APPENDICES

4.1 Financial statements

Consolidated balance sheet

30 Se e be 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

[illegible]: [illegible] G[illegible]: RMB T[illegible]: [illegible]

Items	30 September 2019	31 December 2018
Current assets:		
C [illegible]	10,307,237,302.85	8,546,521,777.04
F [illegible]	1,344,673,568.10	616,123,764.39
B [illegible]	258,620,513.78	712,510,581.95
T [illegible]	4,463,034,533.86	3,623,640,740.82
R [illegible]	471,597,865.70	—
P [illegible]	596,927,301.93	472,144,580.30
O [illegible]	577,591,869.92	447,434,579.55
I [illegible]: I [illegible]	9,995,755.01	11,660,016.68
D [illegible]	36,917,475.21	19,731,451.25
I [illegible]	3,858,842,830.18	3,287,392,199.46
N [illegible]	—	—
A [illegible]	1,162,820,637.56	—
O [illegible]	368,970,686.90	295,958,970.62
T [illegible]	23,410,317,110.78	18,001,727,194.13
Non-current assets:		
D [illegible]	117,956,750.00	67,562,000.00
L [illegible]	21,198,447,942.66	21,427,527,810.80
O [illegible]	100,986,503.54	126,313,106.69
O [illegible]	2,100,733,208.89	2,505,806,955.75
F [illegible]	7,291,387,236.53	7,083,251,505.14
C [illegible]	2,942,095,697.03	2,039,800,319.91
R [illegible]	433,996,758.51	—
I [illegible]	7,873,710,459.21	7,151,343,109.87
D [illegible]	2,676,735,574.42	2,040,773,501.88
G [illegible]	9,187,137,617.57	8,853,913,413.52
L [illegible]	114,180,385.70	95,198,631.30
D [illegible]	242,021,035.79	173,134,814.17
O [illegible]	879,591,445.02	985,009,024.32
T [illegible]	55,158,980,614.87	52,549,634,193.35
T [illegible]	78,569,297,725.65	70,551,361,387.48

Consolidated balance sheet *(Continued)*

30 Se e be 2019

Items	30 September 2019	31 December 2018
Current liabilities:		
S [illegible]	7,440,018,220.78	5,607,192,955.63
B [illegible]	266,942,486.20	149,003,072.96
T [illegible]	2,233,670,981.77	2,184,280,272.14
[illegible]	562,709,265.76	578,701,499.77
T [illegible]	451,969,450.66	478,905,270.26
O [illegible]	4,178,903,272.34	3,237,217,890.12
I [illegible] : I [illegible]	220,768,148.00	187,344,429.18
D [illegible]	139,956,011.68	125,420,505.60
C [illegible]	388,047,456.85	530,896,724.79
N [illegible]	2,206,056,772.37	4,929,603,365.34
O [illegible]	1,599,149,293.47	227,445,337.32
T [illegible]	19,327,467,200.20	17,923,246,388.33
Non-current liabilities:		
L [illegible]	8,816,140,333.28	8,630,661,547.43
B [illegible]	5,781,204,728.90	4,039,456,986.21
L [illegible]	307,212,833.42	—
L [illegible]	252,679,111.96	416,889,805.19
D [illegible]	358,341,043.66	363,489,177.57
D [illegible]	2,895,818,060.31	2,908,359,008.27
O [illegible]	2,878,227,018.69	2,676,545,098.82
T [illegible]	21,289,623,130.22	19,035,401,623.49
T [illegible]	40,617,090,330.42	36,958,648,011.82
Equity:		
P [illegible] ([illegible])	2,562,898,545.00	2,563,060,895.00
C [illegible]	11,918,086,638.94	10,544,648,359.54
L : T [illegible]	—	1,711,169.00
O [illegible]	–238,833,703.62	–274,779,732.99
S [illegible]	2,373,685,050.45	2,374,999,312.51
[illegible]	14,017,910,346.50	12,771,518,762.43
T [illegible] ([illegible]) [illegible]	30,633,746,877.27	27,977,736,427.49
N [illegible]	7,318,460,517.96	5,614,976,948.17
T [illegible] ([illegible])	37,952,207,395.23	33,592,713,375.66
T [illegible] ([illegible])	78,569,297,725.65	70,551,361,387.48

Lega Re [illegible]: **Chen Qiyu**

Ch ef F a c a Off ce : **Guan Xiaohui**

D ec f he Acc g De a e : **Chen Zhanyu**

Balance Sheet of the Parent Company

30 Se[illegible]e[illegible]be[illegible] 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

[illegible] G[illegible]: RMB T[illegible]

Items	30 September 2019	31 December 2018
Current assets:		
C[illegible]	1,106,498,344.52	850,102,168.54
F[illegible]		
P[illegible]		
O[illegible]	6,407,634,690.21	6,914,735,852.92
I[illegible]: I[illegible]	299,410,098.84	230,691,574.83
D[illegible]	354,609,680.05	307,409,680.05
I[illegible]	—	—
N[illegible]	2,536,000,000.00	1,625,000,000.00
O[illegible]	239,000,000.00	158,570,000.00
T[illegible]	10,289,133,034.73	9,548,408,021.46
Non-current assets:		
D[illegible]	6,011,804,080.60	5,465,151,645.71
L[illegible]	23,961,991,164.92	22,999,277,541.00
O[illegible]	37,689,534.30	37,626,487.24
O[illegible]	147,179,403.98	184,188,803.45
F[illegible]	6,217,807.54	7,158,298.77
C[illegible]	2,305,418.41	2,305,418.41
I[illegible]	1,398,139.68	1,840,272.04
D[illegible]		
G[illegible]		
L[illegible]		
D[illegible]		
T[illegible]	30,168,585,549.43	28,697,548,466.62
T[illegible]	40,457,718,584.16	38,245,956,488.08

Balance Sheet of the Parent Company *(Continued)*

30 Se e be 2019

Items	30 September 2019	31 December 2018
Current liabilities:		
S	3,825,000,000.00	2,959,000,000.00
B		
R		
C		
	94,480,035.63	124,637,901.93
T	25,239,506.72	43,694,651.68
O	1,715,449,403.09	1,357,247,173.94
I : I	213,542,735.45	172,658,261.16
D	229,468.00	229,468.00
N -	1,267,088,795.71	3,769,010,861.94
O	1,304,675,980.01	5,313,103.87
T	8,231,933,721.16	8,258,903,693.36
Non-current liabilities:		
L	346,740,000.00	66,740,000.00
B	5,781,204,728.90	4,039,456,986.21
L		
D	325,000.00	550,000.00
D	1,151,018,873.79	1,151,018,873.79
O -		
T -	7,279,288,602.69	5,257,765,860.00
T	15,511,222,323.85	13,516,669,553.36
Equity:		
P ( )	2,562,898,545.00	2,563,060,895.00
C	14,247,927,508.28	14,231,054,756.04
L : T	—	1,711,169.00
O	–327,370,661.53	–279,100,142.24
S	1,247,565,522.50	1,247,565,522.50
	7,215,475,346.06	6,968,417,072.42
T (')	24,946,496,260.31	24,729,286,934.72
T (')	40,457,718,584.16	38,245,956,488.08

Lega Re e e a e: **Chen Qiyu** *Ch ef F a c a Off ce :* **Guan Xiaohui** *D ec f he Acc g De a e :* **Chen Zhanyu**

Consolidated Income Statement

Ja a – Se e be 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

G : RMB T

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. T	7,054,850,058.34	6,283,385,304.74	21,227,618,679.11	18,142,384,871.95
I : O	7,054,850,058.34	6,283,385,304.74	21,227,618,679.11	18,142,384,871.95
II. T	6,709,469,373.75	5,992,960,058.43	19,857,997,730.00	16,934,362,208.60
I : O	2,937,674,384.28	2,624,459,330.67	8,536,657,487.53	7,570,324,025.58
T	53,919,704.29	65,311,065.96	170,438,628.37	185,482,861.22
S	2,407,588,465.78	2,156,969,593.90	7,406,036,962.51	5,961,359,845.63
G A	681,653,157.36	598,132,921.36	1,800,645,744.87	1,608,430,292.39
R	440,645,827.79	405,212,249.70	1,290,028,940.00	1,114,194,226.61
F	187,987,834.25	142,874,896.84	654,189,966.72	494,570,957.17
I : I 356331T (,8)6.2(96.84)-2662.1(654,189,96)6.2(6.72)-2668.4(4)6.2(94,57 50.5(8 25798.98 356331T (,8)6.				

Consolidated Income Statement *(Continued)*

Ja a – Se e be 2019

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. O [illegible]	–9,016,755.16	–122,010,941.32	34,958,479.93	–532,197,468.31
O [illegible]	7,142,372.12	–173,180,224.69	35,946,029.37	–571,964,925.72
( ) O [illegible]	144,152.81	3,756,815.51	–26,694,169.11	–101,521,914.06
1. C [illegible]	—	—	—	—
2. S [illegible]	—	—	—	—
3. C [illegible]	144,152.81	3,756,815.51	–26,694,169.11	–101,521,914.06
4. C [illegible]	—	—	—	—
( ) O [illegible]	6,998,219.31	–176,937,040.20	62,640,198.48	–470,443,011.66
1. S [illegible]	–27,514,726.87	22,492,035.64	–57,540,529.80	29,149,580.97
2. D [illegible]	34,512,946.18	–199,429,075.84	120,180,728.28	–499,592,592.63
O [illegible]	–16,159,127.28	51,169,283.37	–987,549.44	39,767,457.41
II. T [illegible]	626,951,292.40	479,073,767.81	2,490,555,469.23	1,806,839,053.77
T [illegible]	554,726,673.16	360,501,362.79	2,099,650,177.36	1,522,187,428.09
T [illegible]	72,224,619.24	118,572,405.02	390,905,291.87	284,651,625.68
III. E [illegible]:				
( ) B [illegible] (/)	0.22	0.20	0.81	0.83
( ) D [illegible] (/)	0.22	0.20	0.81	0.83

Lega Re e e a [illegible]: **Chen Qiyu**

Ch ef F a c a Off ce : **Guan Xiaohui**

D ec f he Acc g De a e : **Chen Zhanyu**

Income Statement of the Parent Company

Ja a – Se e be 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

: G : RMB T :

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. O	3,815,974.06	—	5,685,313.69	9,433.96
L : O	—	—	—	—
T	1,138,885.77	—	2,411,699.94	43,754.06
S	—	—	—	—
G A	65,458,328.69	72,278,881.00	136,505,943.90	151,588,516.01
R	1,400,270.20	—	2,952,245.60	—
F	24,847,472.18	29,794,031.27	105,319,187.87	78,043,266.55
I : I	143,806,935.92	120,916,769.27	411,681,720.73	331,017,960.01
I	110,395,009.96	101,566,901.47	300,636,180.35	266,631,390.40
A	—	—	—	—
C	—	—	—	—
P : O	110,486.49	75,000.00	300,849.09	225,000.00
I ("–")	438,727,482.59	409,853,353.52	1,342,948,533.13	1,328,284,941.99
I : I	430,736,612.25	389,199,792.25	1,250,403,969.29	1,156,577,651.49
G ("–")				
G ("–")	–14,794,694.59	66,221,631.43	–36,067,868.78	90,531,856.25
G ("–")	7,349.80	–886.58	7,349.80	–886.58
II. O ("–")	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
P : N -				
L : N -				
III. T ("–")	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
L : I				
I . N ("–")	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
( ) N ("–")	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
( ) N ("–")	—	—	—	—

4.2 Information on adjustments to the initial implementation of financial statements at the beginning of the year for the initial implementation of New Financial Instruments Standards, New Income Standards and New Lease Standards

Consolidated balance sheet

: G : RMB

Items	31 December 2018	1 January 2019	Adjustment
Current assets:			
C %	8,546,521,777.04	8,546,521,777.04	
H % %	616,123,764.39	616,123,764.39	
B	712,510,581.95	712,510,581.95	
T %	3,623,640,740.82	3,623,640,740.82	
P	472,144,580.30	472,144,580.30	
O	447,434,579.55	447,434,579.55	
I %: I	11,660,016.68	11,660,016.68	
D % %	19,731,451.25	19,731,451.25	
I	3,287,392,199.46	3,287,392,199.46	

Items	31 December 2018	1 January 2019	Adjustment
Non-current liabilities:			
L[illegible]	8,630,661,547.43	8,630,661,547.43	
B[illegible]	4,039,456,986.21	4,039,456,986.21	
I[illegible]: P[illegible]	—	—	
P[illegible]	—	—	
L[illegible]	—	325,992,167.00	–325,992,167.00
L[illegible]	416,889,805.19	398,095,841.52	18,793,963.67
D[illegible]	363,489,177.57	363,489,177.57	
D[illegible]	2,908,359,008.27	2,908,359,008.27	
O[illegible]	2,676,545,098.82	2,676,545,098.82	
T[illegible]	19,035,401,623.49	19,342,599,826.82	–307,198,203.33
T[illegible]	36,958,648,011.82	37,348,299,890.45	–389,651,878.63
Equity (or shareholders' interests):			
P[illegible] ([illegible])	2,563,060,895.00	2,563,060,895.00	
C[illegible]	10,544,648,359.54	10,544,648,359.54	
L[illegible]	1,711,169.00	1,711,169.00	
O[illegible]	–274,779,732.99	–274,779,732.99	
S[illegible]	2,374,999,312.51	2,374,999,312.51	
[illegible]	12,771,518,762.43	12,771,518,762.43	
T[illegible]	27,977,736,427.49	27,977,736,427.49	
N[illegible]	5,614,976,948.17	5,614,976,948.17	
T[illegible] E[illegible] ([illegible])	33,592,713,375.66	33,592,713,375.66	
T[illegible] ([illegible])	70,551,361,387.48	70,941,013,266.11	–389,651,878.63

E[illegible]:

F[illegible] 1 J[illegible] 2019, [illegible] G[illegible] N[illegible] L[illegible] S[illegible] MOF.

I[illegible] N[illegible] L[illegible] S[illegible], [illegible] G[illegible] N[illegible] L[illegible] S[illegible] 2019. T[illegible] G[illegible]'[illegible].

Balance Sheet of the Parent Company

[illegible]: RMB

Items	31 December 2018	1 January 2019	Adjustment
Current assets:			
C[illegible]	850,102,168.54	850,102,168.54	
O[illegible]	6,914,735,852.92	6,914,735,852.92	
I[illegible]: I[illegible]	230,691,574.83	230,691,574.83	
D[illegible]	307,409,680.05	307,409,680.05	
N[illegible]	1,625,000,000.00	1,625,000,000.00	
O[illegible]	158,570,000.00	158,570,000.00	
T[illegible]	9,548,408,021.46	9,548,408,021.46	
Non-current assets:			
D[illegible]	5,465,151,645.71	5,465,151,645.71	
L[illegible]	22,999,277,541.00	22,999,277,541.00	
O[illegible]	37,626,487.24	37,626,487.24	
O[illegible]	184,188,803.45	184,188,803.45	
F[illegible]	7,158,298.77	7,158,298.77	
C[illegible]	2,305,418.41	2,305,418.41	
I[illegible]	1,840,272.04	1,840,272.04	
T[illegible]	28,697,548,466.62	28,697,548,466.62	
T[illegible]	38,245,956,488.08	38,245,956,488.08	
Current liabilities:			
S[illegible]	2,959,000,000.00	2,959,000,000.00	
[illegible]	124,637,901.93	124,637,901.93	
T[illegible]	43,694,651.68	43,694,651.68	
O[illegible]	1,357,247,173.94	1,357,247,173.94	
I[illegible]: I[illegible]	172,658,261.16	172,658,261.16	
D[illegible]	229,468.00	229,468.00	
N[illegible]	3,769,010,861.94	3,769,010,861.94	
O[illegible]	5,313,103.87	5,313,103.87	
T[illegible]	8,258,903,693.36	8,258,903,693.36	

Items	31 December 2018	1 January 2019	Adjustment
Non-current liabilities:			
L[illegible]	66,740,000.00	66,740,000.00	
B[illegible]	4,039,456,986.21	4,039,456,986.21	
I[illegible]: P[illegible]	—	—	
P[illegible]	—	—	
D[illegible]	550,000.00	550,000.00	
D[illegible]	1,151,018,873.79	1,151,018,873.79	
T[illegible]	5,257,765,860.00	5,257,765,860.00	
T[illegible]	13,516,669,553.36	13,516,669,553.36	
E[illegible] ([illegible]):			
P[illegible] ([illegible])	2,563,060,895.00	2,563,060,895.00	
C[illegible]	14,231,054,756.04	14,231,054,756.04	
L[illegible]	1,711,169.00	1,711,169.00	
O[illegible]	–279,100,142.24	–279,100,142.24	
S[illegible]	1,247,565,522.50	1,247,565,522.50	
[illegible]	6,968,417,072.42	6,968,417,072.42	
T[illegible] ([illegible])	24,729,286,934.72	24,729,286,934.72	
T[illegible] ([illegible])	38,245,956,488.08	38,245,956,488.08	

4.3 Explanation on retrospective adjustments to previous comparative data for the initial implementation of New Financial Instruments Standards and New Lease Standards

F[illegible] 1 J[illegible] 2019, [illegible] G[illegible] N[illegible] L[illegible] S[illegible] MOF.

I[illegible] N[illegible] L[illegible] S[illegible], [illegible] G[illegible] N[illegible] L[illegible] S[illegible] 2019. T[illegible] G[illegible] [illegible].

4.4 Audited report

N[illegible]